Meeting the FDA recommendations, Skuldtech has developed pharmacogenomic services based on NGS technologies and its extensive experience able to support pharmaceutical industry to optimize clinical trials.
The goal of clinical pharmacogenomics analysis, which enables also optimization of clinical trial design, is to facilitate evaluation of clinical pharmacological parameters such as:
Safety - Toxicity - adverse effects
Skuldtech has established expertise and tools that enable the company to meet FDA guidelines in an accurate and effective manner, while serving the needs of pharmaceutical and biotechnology companies with respect to clinical pharmacogenomics.
Over 13 years experience in pharmacogenomics: For over twelve years, Skuldtech has been developing tools and processes, and consolidating its expertise in identifying genomic biomarkers for research and diagnosis applications, as well as for helping to develop new drugs.
Recognized by leaders in the field: Skuldtech has collaborated with Roche Diagnostics on the first analysis of transcriptome data on the Roche/454 Life Sciences Sequencer System and on elaborating experimental protocols with Solexa.
Expertise in clinical pharmacology: Skuldtech benefits from significant experience in pharmacological development for clinical trials. The company is currently in Phase III clinical trials for an oncology application; Phase II for an application for neurodegenerative diseases with diagnoses associated with therapies (companion diagnostics); and in the clinical phase (study phase demonstrating clinical benefits) for a disease progression diagnosis/prognosis in oncology.
Cutting-edge bioinformatics tools: Skuldtech leverages its proprietary bioinformatics platform, which can process millions of pieces of data obtained from New Generation Sequencing (NGS) technologies. This unique bioinformatics platform interprets data and integrates it into all types of bioinformatics databases.
Biostatistical data integration: Skuldtech integrates all of its pharmacogenomic analyses into a specific biostatistical platform that integrates biostatistical tools that were specifically designed to analyze genomic data as well as more traditional models. These biostatistical approaches also cover both experimental schemas and specific interpretation of biological New Generation Sequencing (NGS) data.
If you require any additional information concerning these pharmacogenomic services provided by our company, you can download our presentation or contact our commercial department :
T: +33(0)467 419 748 or Email: firstname.lastname@example.org.
Skuldtech is specialized in the discovery of
new Biomarkers and the development of Diagnostics
focused on personalized medicine applications.
This expertise enables the company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics
associated with new treatments, especially in
cancer, neurodegenerative and infectious diseases.